Home Series

Peterson-KFF Health System Tracker

The Peterson-KFF Health System Tracker is an online hub monitoring how well the U.S. health system is operating through key quality and cost measures. A partnership of the Peterson Center on Healthcare and KFF, the Tracker documents trends in Health Spending, Quality of Care, Access & Affordability, and Health & Wellbeing through issue briefs and downloadable chart collections. The Tracker also includes the Interactive Health Spending Explorer tool, which helps users analyze more than 50 years of health expenditure data, and a Health System Dashboard, which provides quick and easy access to the latest, most relevant statistics.

View the Latest: Health System Tracker

Filter

List Grid

1-10 of 185 results

  • How Much is Health Spending Expected to Grow?

    Feature

    This chart collection explores how much health spending is expected to grow in the coming years, with a look at growth in prescription drug spending, out-of-pocket spending, and related trends.

  • Is This A Healthcare Economy?

    Issue Brief

    This analysis examines recent jobs growth in health care and how it compares to the rest of the economy. Health care employment has grown faster than other sectors of the economy, with jobs in physician offices, hospitals, outpatient care centers, home health, and other settings increasing over the past year even as the rest of the job market plateaued. 

  • What Are the Recent Trends in Health Sector Employment

    Issue Brief

    Health care employment continues to grow even as hiring across other sectors has plateaued. The health sector added nearly 379,000 jobs over the past year, a 2% increase, compared with just 0.2% growth in other non-farm employment, with outpatient care among the fastest-growing health care settings.

  • How TrumpRx Brand-Name Drug Prices Compare to Other Countries

    Issue Brief

    TrumpRx prices for brand-name drugs are about as likely to be higher as lower compared to average prices in other wealthy countries, according to an analysis that compares 32 brand-name drugs (without generics or biosimilars) on the TrumpRx website with publicly available prices in one or more of 11 OECD member countries.

  • Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive

    News Release

    Consumers who buy brand-name prescription drugs without an available generic or biosimilar at the prices available through the new TrumpRx website are about as likely to pay more as pay less for those drugs relative to the publicly listed prices available in other comparatively wealthy countries, a new KFF analysis finds. The Trump administration has promoted the TrumpRx website as a way for consumers to get the lowest prices for prescription medications in the world, drawing on…

  • How Much and Why Premiums Are Going Up for Small Businesses in 2027

    Other Post

    Small businesses that offer health insurance to their employees could see health costs rise in 2027, according to an analysis of preliminary rate filings from all 50 states and DC. Nearly 300 insurers offering small group coverage reported a median proposed premium increase of 14% for next year.

  • In Preliminary Rate Filings, ACA Marketplace Insurers Largely Propose Double-Digit Premium Increase For 2027, Following a Steep Climb This Year 

    News Release

    ACA Marketplace insurers are proposing a median premium increase of 14% for 2027— indicating a likely second consecutive year of double-digit increases, according to a new analysis of preliminary rate filings in 16 states and DC. If these increases hold, typical premiums for insurers participating in the ACA Marketplaces would jump by more than one-third between 2025 and 2027.